

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

pBabepuro-myc-ER

RRID:Addgene_19128

Type: Plasmid

Proper Citation

RRID:Addgene_19128

Plasmid Information

URL: <http://www.addgene.org/19128>

Proper Citation: RRID:Addgene_19128

Insert Name: c-myc

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:15367674](#)

Vector Backbone Description: Backbone Size:5169; Vector Backbone:pBabepuro3:hbER tam; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Comments: Please see Littlewood et al., Nucleic Acids Res. 1995 May 25;23(10):1686-90 for more information regarding the mutant hormone binding domain of the mouse estrogen receptor (hbER Tam).

Plasmid Name: pBabepuro-myc-ER

Record Creation Time: 20220422T222044+0000

Record Last Update: 20260905T075333+0000

Ratings and Alerts

No rating or validation information has been found for pBabepuro-myc-ER.

No alerts have been found for pBabepuro-myc-ER.

Data and Source Information

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Choi J, et al. (2025) Recombinant Cell-Permeable Puromycin N-Acetyltransferase Confers Puromycin Resistance by Direct Protein Transduction. *Journal of microbiology and biotechnology*, 35, e2502049.

Metz EP, et al. (2022) Elevating SOX2 Downregulates MYC through a SOX2:MYC Signaling Axis and Induces a Slowly Cycling Proliferative State in Human Tumor Cells. *Cancers*, 14(8).

Akimov SS, et al. (2021) Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics. *Human molecular genetics*, 30(24), 2469.

Scarpa M, et al. (2021) PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 β -Mediated c-Myc and Pim-1 Proteasomal Degradation. *Molecular cancer therapeutics*, 20(4), 676.

Scarpa M, et al. (2021) Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. *Oncotarget*, 12(18), 1763.

Lankes K, et al. (2020) Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. *Molecular oncology*, 14(12), 3048.

Chao HX, et al. (2019) Evidence that the human cell cycle is a series of uncoupled, memoryless phases. *Molecular systems biology*, 15(3), e8604.

Pulikkan JA, et al. (2018) CBF β -SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. *Cell*, 174(1), 172.

Kurashima K, et al. (2018) Pol η , a Y-family translesion synthesis polymerase, promotes cellular tolerance of Myc-induced replication stress. *Journal of cell science*, 131(12).

Spehalski E, et al. (2017) MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress. *Cancer research*, 77(19), 5327.

Maina PK, et al. (2016) c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer. *Oncotarget*, 7(46), 75585.

Muvarak N, et al. (2015) c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. *Molecular cancer research : MCR*, 13(4), 699.

Lu L, et al. (2015) Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma. *Molecular carcinogenesis*, 54(11), 1467.

Akita H, et al. (2014) MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. *Cancer research*, 74(20), 5903.

Han H, et al. (2013) A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. *Hepatology (Baltimore, Md.)*, 57(6), 2378.

Neri F, et al. (2012) Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. *Molecular and cellular biology*, 32(4), 840.